Drug Search Results
More Filters [+]

Pentoxyverine

Alternative Names: pentoxyverine
Latest Update: 2023-10-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: M1 Antagonist,S1R Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Australia | Austria | Belgium | Brazil | China | Egypt | Finland | France | Greece | Hong Kong | Italy | Korea | Portugal | Saudi Arabia | Slovakia | Slovenia | South Africa | Sweden | Taiwan | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Pentoxyverine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT02183649

P1

Completed

Healthy Volunteers

2009-12-01

Recent News Events